GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (BSP:H1ZN34) » Definitions » Stock Based Compensation

Horizon Therapeutics (BSP:H1ZN34) Stock Based Compensation : R$1,065 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Horizon Therapeutics Stock Based Compensation?

Horizon Therapeutics's Stock Based Compensation for the three months ended in Jun. 2023 was R$293 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was R$1,065 Mil.


Horizon Therapeutics Stock Based Compensation Historical Data

The historical data trend for Horizon Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Stock Based Compensation Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 446.05 374.41 754.37 1,238.93 955.19

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.90 236.33 233.89 302.72 292.53

Horizon Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,065 Mil.


Horizon Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (BSP:H1ZN34) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Horizon Therapeutics (BSP:H1ZN34) Headlines

No Headlines